Hepatic Cytochrome P450 Activity and Nitric Oxide Production During Multiple Ovalbumin Challenges

Tanino, Tadatoshi; Bando, Toru; Okada, Yuna; Nojiri, Yukie; Hashimoto, Katsufumi; Ueda, Yasuyuki; Sakurai, Eiichi

doi:10.1007/s13318-018-0527-1

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have suggested that post-transcriptional mechanisms may also modulate CYP activity. A chronic allergic murine model induced by repeated administration of ovalbumin showed down-regulation of CYP 1A2, CYP2C, 2E1, and CYP3A activity, although CYP protein expression remained unchanged relative to that of control animals ( Tanino et al, 2019 ). IL-1β challenge in cultured rat hepatocytes decreased CYP3A1 protein expression by 40% and reduced its activity within 6 h ( Lee, Pohl, & Morgan, 2009 ).…”

Section: Regulation Of Dmets By Inflammationmentioning

confidence: 99%

Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment

Stanke‐Labesque

Gautier-Veyret

Chhun

et al. 2020

Pharmacology & Therapeutics

131

147

View full text Add to dashboard Cite

Inflammation is an evolutionary process that allows survival against acute infection or injury. Inflammation is also a pathophysiological condition shared by numerous chronic diseases. In addition, inflammation modulates important drug-metabolizing enzymes and transporters (DMETs), thus contributing to intra- and interindividual variability of drug exposure. A better knowledge of the impact of inflammation on drug metabolism and its related clinical consequences would help to personalize drug treatment. Here, we summarize the kinetics of inflammatory mediators and the underlying transcriptional and post-transcriptional mechanisms by which they contribute to the inhibition of important DMETs. We also present an updated overview of the effect of inflammation on the pharmacokinetic parameters of most of the drugs that are DMET substrates, for which therapeutic drug monitoring is recommended. Furthermore, we provide opinions on how to integrate the inflammatory status into pharmacogenetics, therapeutic drug monitoring, and population pharmacokinetic strategies to improve the personalization of drug treatment for each patient.

show abstract

Section: Regulation Of Dmets By Inflammationmentioning

confidence: 99%